Design Therapeutics Q1 net loss $17.7M; cash $229.7M funds into 2029

Design Therapeutics, Inc.

2025-Q1 EPS reported -$0.31

R&D expenses $15.4M, G&A $5.0M for Q1 2025; net loss $17.7M.
Cash and securities $229.7M as of March 31, 2025; expected runway into 2029.
Phase 1 SAD trial ongoing for DT-216P2 (FA); MAD patient study planned mid-2025.
Favorable Phase 1 data for DT-168 (FECD); Phase 2 biomarker trial planned H2 2025.
Appointed Chris Storgard, M.D., as Chief Medical Officer in April 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.